Inconsistency of different methods for assessing ex vivo platelet function: Relevance for the detection of aspirin resistance

Haematologica

Volumn 95, Issue 12, 2010, Pages 2095-2101

  Renda, Giulia ^a   Zurro, Maria ^a   Malatesta, Gelsomina ^a   Ruggieri, Benedetta ^a   de Caterina, Raffaele ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Aspirin resistance; Platelet aggregation; Platelet function; Serum thromboxane B2

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; ARACHIDONIC ACID; COLLAGEN; CYCLOOXYGENASE 1; THROMBOXANE B2;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME ACTIVITY; ERYTHROCYTE COUNT; EX VIVO STUDY; FEMALE; HEMOSTASIS; HUMAN; LEUKOCYTE COUNT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION;

ADENOSINE DIPHOSPHATE; ADULT; ARACHIDONIC ACID; ASPIRIN; BLOOD PLATELETS; COLLAGEN; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; THROMBOXANE B2; YOUNG ADULT;

EID: 78649873511     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.027102     Document Type: Article

References (31)

1. McKee S, Sane D, Dellargyris E. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost. 2002;88(5): 711-5.
2. Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost. 2005;3(6): 1309-11.
3. Patrono C, Rocca B. Drug insight: aspirin resistance - fact or fashion? Nat Clin Pract Cardiovasc Med. 2007;4(1):42-50.
4. Crowe B, Abbas S, Meany B, de Haan J, Cahill MR. Detection of aspirin resistance by PFA-100: prevalence and aspirin compliance in patients with chronic stable angina. Semin Thromb Hemost. 2005;31(4):420-5.
5. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88(3):230-5.
6. Harrison P, Segal H, Blasbery K, Furtado C, Silver L, Rothwell PM. Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-ofcare platelet function tests with optical aggregometry. Stroke. 2005;36(5):1001-5.
7. Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke. 2004;35(1): 175-8.
8. Hovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J. 2007;153(2):175-81.
9. Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2009;30 (4):426-35.
10. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal Nature. 1962;194:927-9.
11. Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost. 1998;24(2):195-202.
12. Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost. 2006;4(2):312-9.
13. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982;69(6): 1366-72.
14. Pedersen AK, FitzGerald GA. Cyclo - oxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing. Clin Pharmacol Ther.1985;37(1):36-42.
15. Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res.1980;17(3-4):317-27.
16. Capone ML, Sciulli MG, Tacconelli S, Grana M, Ricciotti E, Renda G, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol. 2005;45(8):1295-301.
17. Harrison P, Robinson MS, Mackie IJ, Joseph J, McDonald SJ, Liesner R, et al. Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis. Blood Coagul Fibrinolysis. 1999;10(1):25-31.
18. Kundu SK, Heilmann E, Sio R, Garcia C, Ostgaard R. Characterization of an in vitro platelet function analyzer - PFA-100. Clin Appl Thromb Hemost 1996;235(2):134-40.
19. Ortel TL, James AH, Thames EH, Moore KD, Greenberg CS. Assessment of primary hemostasis by PFA-100 analysis in a tertiary care center. Thromb Haemost. 2000; 84(1):93-7.
20. Eugster M, Reinhart WH. The influence of the haematocrit on primary haemostasis in vitro. Thromb Haemost. 2005;94(6):1213-8.
21. Mannini L, Marcucci R, Paniccia R, Antonucci E, Giglioli C, Valente S, et al. Erythrocyte deformability and white blood cell count are associated with aspirin resistance in high-risk vascular patients. Clin Hemorheol Microcirc. 2006;35(1-2):175-81.
22. Gori AM, Cesari F, Marcucci R, Giusti B, Paniccia R, Antonucci E, et al. The balance between pro- and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients. Atherosclerosis. 2009;202(1):255-62.
23. Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation.2008;117(11):1449-59.
24. Harrison P, Segal H, Silver L, Syed A, Cuthbertson FC, Rothwell PM. Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests. Platelets.2008;19(2):119-24.
25. Mortensen J, Poulsen TS, Grove EL, Refsgaard J, Nielsen HL, Pedersen SB, et al. Monitoring aspirin therapy with the Platelet Function Analyzer-100. Scand J Clin Lab Invest. 2008;68(8):786-92.
26. Grove EL, Hvas AM, Johnsen HL, Hedegaard SS, Pedersen SB, Mortensen J, et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost. 2010;103(6):1245-53.
27. Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin resistance. J Am Coll Cardiol. 2009; 53(8):667-77.
28. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. 1987;69(1):180-6.
29. Sciulli MG, Renda G, Capone ML, Tacconelli S, Ricciotti E, Manarini S, et al. Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease. Clin Pharmacol Ther. 2006;80(2):115-25.
30. Nicholson NS, Panzer-Knodle SG, Haas NF, Taite BB, Szalony JA, Page JD, et al. Assessment of platelet function assays. Am Heart J. 1998;135(5 Pt 2 Su):S170-8.
31. Marcucci R, Paniccia R, Antonucci E, Gori AM, Fedi S, Giglioli C, et al. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events. Am J Cardiol. 2006;98(9):1156-9.